GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Clinical Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population

Phase 1

Completed

Conditions: Nutritional Status

Interventions: Drug: Placebo
Drug: Creatine

First Posted Date: 2014-02-10

Last Posted Date: 2018-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT02058654

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State

Phase 1

Completed

Conditions: Urologic Diseases

Interventions: Drug: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
Drug: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule

First Posted Date: 2014-02-03

Last Posted Date: 2018-09-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 78

Registration Number: NCT02052713

Locations: 🇬🇧
GSK Investigational Site, Belfast, United Kingdom

This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa

Phase 4

Completed

Conditions: Hepatitis B

Interventions: Biological: Engerix™-B Kinder

First Posted Date: 2014-02-03

Last Posted Date: 2018-06-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 301

Registration Number: NCT02052661

Locations: 🇩🇪
GSK Investigational Site, Neumuenster, Germany

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

Phase 4

Completed

Conditions: Skin Diseases

Interventions: Drug: 3% Benzoyl Peroxide
Drug: 3% Benzoyl Peroxide Placebo
Drug: Neutrogena Rapid Clear®

First Posted Date: 2014-02-03

Last Posted Date: 2015-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 90

Registration Number: NCT02052752

Locations: 🇺🇸
GSK Investigational Site, High Point, North Carolina, United States

A Validation and Dosimetry Study of GSK2634673F PET Ligand

Phase 1

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Other: GSK2634673F

First Posted Date: 2014-02-03

Last Posted Date: 2018-06-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 19

Registration Number: NCT02052297

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

Phase 3

Completed

Conditions: Herpes Zoster

Interventions: Biological: Herpes Zoster vaccine GSK 1437173A
Biological: Boostrix

First Posted Date: 2014-02-03

Last Posted Date: 2018-04-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 935

Registration Number: NCT02052596

Locations: 🇺🇸
GSK Investigational Site, Richmond, Virginia, United States

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

Phase 1

Completed

Conditions: Cachexia

Interventions: Drug: GSK2881078
Drug: Placebo

First Posted Date: 2014-01-27

Last Posted Date: 2018-07-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 99

Registration Number: NCT02045940

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: GSK2140944 capsule
Drug: GSK2140944 tablet
Drug: Itraconazole capsule

First Posted Date: 2014-01-27

Last Posted Date: 2017-07-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 46

Registration Number: NCT02045849

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

Phase 2

Completed

Conditions: Infections, Bacterial

Interventions: Drug: GSK2140944 Lyophile
Drug: GSK2140944 Capsules

First Posted Date: 2014-01-27

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 126

Registration Number: NCT02045797

Locations: 🇺🇸
GSK Investigational Site, Houston, Texas, United States

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Phase 3

Completed

Conditions: Herpes Zoster Vaccine
Herpes Zoster

Interventions: Biological: Herpes Zoster vaccine GSK 1437173A
Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™

First Posted Date: 2014-01-27

Last Posted Date: 2021-05-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 865

Registration Number: NCT02045836

Locations: 🇪🇪
GSK Investigational Site, Tartu, Estonia

Home Terms & Conditions Privacy Policy